Quick Answer
Pharmagreen Biotech Inc. reported Net Income of -$875.5 thousand for fiscal year 2022.
Pharmagreen Biotech Inc. — Key Financials by Year
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Net Income | -$875.5K +80.7% |
-$4.53M -82.6% |
-$2.48M -223.5% |
-$767.5K +28.5% |
-$1.07M | — |
| Total Assets | $209.0K -44.0% |
$373.1K +40.1% |
$266.2K -57.8% |
$630.3K +40.2% |
$449.4K | — |
| Cash and Equivalents | — | $25.3K +107.4% |
$12.2K -80.5% |
$62.7K | — | — |
| Long-Term Debt | — | — | $30.0K | — | — | — |
| Stockholders Equity | -$1.82M -7.7% |
-$1.69M +42.3% |
-$2.93M -251.6% |
-$834.5K +39.9% |
-$1.39M +42.1% |
-$2.40M |
| R&D Expense | — | — | — | $4.0K -48.1% |
$7.6K | — |
| Operating Income | -$1.10M -48.0% |
-$744.1K -53.2% |
-$485.8K +24.4% |
-$642.2K +14.2% |
-$748.7K | — |
| Shares Outstanding | 442.26M +16.0% |
381.17M +297.9% |
95.81M +26.6% |
75.65M +5.6% |
71.62M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2023 | $597.00 | — | -38.0% |
| Net Income | June 30, 2023 | -$162.9K | -164.7% | -313.8% |
| Diluted EPS | June 30, 2022 | $0.00 | — | — |
| Total Assets | June 30, 2023 | $140.3K | -26.6% | -13.9% |
| Cash and Equivalents | June 30, 2022 | $24.3K | +26.2% | +696.8% |
| Long-Term Debt | March 31, 2021 | $31.8K | — | +5.9% |
| Stockholders Equity | June 30, 2023 | -$2.10M | -11.3% | -8.4% |
| R&D Expense | June 30, 2019 | -$32.7K | — | -574.1% |
| Operating Income | March 31, 2023 | -$188.0K | +81.9% | -3.8% |
| Gross Profit | June 30, 2023 | $208.00 | — | +1045.5% |
| Shares Outstanding | June 30, 2023 | 463.96M | +9.3% | +2.0% |
- Pharmagreen Biotech Inc. reported Net Income of -$875.5 thousand for fiscal year 2022.
- Pharmagreen Biotech Inc. showed an increase of +80.7% in Net Income compared to the prior fiscal year.
- Pharmagreen Biotech Inc. reported Total Assets of $209.0 thousand for fiscal year 2022.
- Pharmagreen Biotech Inc. showed a decrease of -44.0% in Total Assets compared to the prior fiscal year.
- Pharmagreen Biotech Inc. reported Cash and Equivalents of $25.3 thousand for fiscal year 2021.
- Pharmagreen Biotech Inc. showed an increase of +107.4% in Cash and Equivalents compared to the prior fiscal year.
- Pharmagreen Biotech Inc. reported Long-Term Debt of $30.0 thousand for fiscal year 2020.
- Pharmagreen Biotech Inc. reported Stockholders Equity of -$1.82 million for fiscal year 2022.
- Pharmagreen Biotech Inc. showed a decrease of -7.7% in Stockholders Equity compared to the prior fiscal year.
- Pharmagreen Biotech Inc. reported R&D Expense of $4.0 thousand for fiscal year 2019.
- Pharmagreen Biotech Inc. showed a decrease of -48.1% in R&D Expense compared to the prior fiscal year.
- Pharmagreen Biotech Inc. reported Operating Income of -$1.10 million for fiscal year 2022.
- Pharmagreen Biotech Inc. showed a decrease of -48.0% in Operating Income compared to the prior fiscal year.
- Pharmagreen Biotech Inc. reported Shares Outstanding of 442.26 million shares for fiscal year 2022.
- Pharmagreen Biotech Inc. showed an increase of +16.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: